NEWMAN MARK J 4

What Happened

• Mark J. Newman, Chief Scientific Officer of GeoVax Labs, was granted 17,600 derivative securities on 2026-06-17. The filing reports acquisition at $0.00 (a compensatory award/option grant), so no cash was paid.
• This is a grant (award) rather than a buy or sell. The award becomes a potential future shareholding as the derivative instruments vest and/or are exercised.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22.
• Transaction type: Award/Grant of derivative securities (reported at $0.00); quantity: 17,600.
• Vesting note (F1): The stock option becomes exercisable in three equal annual installments on the first three anniversaries of the grant.
• Shares owned after transaction: not specified in the supplied filing extract.
• Timeliness: Filing occurred five days after the transaction date; Form 4s are generally required within two business days, so this appears later than the typical deadline.

Context

• This was a compensatory grant (derivative award/stock option), not an open-market purchase — it creates the potential to acquire shares in the future once vesting/exercise conditions are met.
• Such grants are common for executives as part of compensation and do not by themselves indicate an immediate personal investment decision.